News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website

 

A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

Al's Comment:

 VB-111 is an experimental gene therapy being tested for use in recurrent Glioblastoma.  As I mentioned in the previous article, the results for the phase 1/2 trial came out on the same day as the results of the phase 3 trial. I do not think I ever saw that happen before.  The Phase 1/2 trial came out very good however, this failed to show any improvement of VB-111 plus Avastin randomized against Avastin alone in recurrent GBM.   If they had the results of the phase1/2 trial before they designed this phase 3 trial, they might have designed it differently as the phase 1/2 trial showed that using VB-111 alone until recurrence, then continuing vb-111 and adding avastin did much better than starting with VB-111 and Avastin at the same time.  This shows that adding combinations doesn't always improve the outcome. Everything needs to be tested and timing is very important.

I am still a fan of VB-111 but think it needs more work to find the optimal way to use it.  


Posted on: 12/25/2019

A randomized controlled phase III study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740